A study evaluating the effect of thromboprophylaxis with enoxaparin at a dose of 20 mg/day in adult patients with renal failure compared the incidence of venous thromboembolism (VTE) with published results in patients without renal insufficiency who were prophylactically treated with enoxaparin at a dose of 40 mg/day. The authors also focused on the incidence of bleeding.

Despite advances in the prevention and treatment of venous thromboembolism, morbidity and mortality associated with this condition remain high in certain risk groups. An international expert group focused on the elderly in its analysis published in the Thrombosis Journal.

Anticoagulants and antiplatelets are a key part of the therapeutic strategies used in the treatment of acute coronary syndromes (ACS). They reduce the risk of acute and late complications, morbidity, and mortality in patients. On the other hand, their main disadvantage is the potential occurrence of bleeding complications. Therefore, the goal of physicians is to use these medications appropriately, maximizing benefits for patients while minimizing the risk of bleeding.

Existing scientific and clinical evidence suggests the involvement of the renin-angiotensin-aldosterone system (RAAS) in the pathophysiology of COVID-19. Some of the initial experimental therapy proposals included various interventions in the RAAS.

The secondary analysis of the TRIUMPH study, recently published in JAMA Cardiology, is likely the first published assessment of time spent in the target blood pressure (BP) range during antihypertensive treatment. This parameter was assessed in patients with moderate hypertension using a low-dose triple combination of antihypertensives (telmisartan 20 mg, amlodipine 2.5 mg, and chlorthalidone 12.5 mg) compared to usual care.

Osteopenia or osteoporosis are known comorbidities of hemophilia and concern many of these patients. What all contributes to their development?

Prague, March 8, 2022 –⁠ Hundreds of thousands of patients in the Czech Republic can soon look forward to a treatment that may positively influence the progression of their disease. The European Medicines Agency (EMA) approved the registration of Jardiance® (empagliflozin) for the treatment of adults with symptomatic chronic heart failure with preserved left ventricular ejection fraction at the beginning of March. It thus becomes the first drug that doctors can prescribe to all patients, regardless of ejection fraction status. EMA had previously approved empagliflozin for the treatment of patients with chronic heart failure with reduced ejection fraction and for the treatment of adults with inadequately controlled type 2 diabetes. The drug was developed by Boehringer Ingelheim.

Thromboembolic disease is a common comorbidity in adult trauma patients, thus making routine thromboprophylaxis appropriate for these patients, most often in the form of low-molecular-weight heparins (LMWH). Standard thromboprophylaxis dosing regimens, however, are often associated with insufficient anti-Xa activity levels. A recently published clinical study by researchers from New York University focused on comparing the standard thromboprophylaxis regimen of enoxaparin with a weight-based dosing regimen in adult trauma patients.

Previous studies have shown that the antidiabetic drug empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure with reduced left ventricular ejection fraction (HFrEF), both in diabetics and non-diabetics. The aim of the EMPEROR-Preserved clinical trial was to supplement data on the efficacy and safety of empagliflozin in a population of patients with heart failure with preserved ejection fraction (HFpEF; EF LK > 40%).

How does brentuximab vedotin (BV) perform as maintenance therapy in real-world practice for patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL) who have undergone autologous hematopoietic stem cell transplantation (HCT) and are at high risk of its failure? This question was posed by authors from King Abdullah International Medical Research Center at King Saud bin Abdulaziz University for Health Sciences in Riyadh. They presented their findings in a poster session at this year's virtual European Society for Blood and Marrow Transplantation (EBMT 2022) congress.

During the recent virtual congress of the European Society for Blood and Marrow Transplantation (EBMT 2022), a study by Saudi experts was presented that explored the response to vaccination against SARS-CoV-2, the causative agent of COVID-19, in patients who had undergone stem cell transplantation (SCT).

Up to 25% of patients with cystic fibrosis are colonized with methicillin-resistant Staphylococcus aureus (MRSA). The first-line drug for acute pulmonary exacerbation is vancomycin. The study presented below examined the efficacy and safety of an alternative treatment with ceftaroline (a 5th generation cephalosporin) for this indication.

Patients with allergic rhinitis require medications with rapid onset and long duration of action. The combination of intranasal antihistamines and corticosteroids has proven effective in the past. The efficacy and safety of a fixed combination of olopatadine and mometasone in a nasal spray (GSP301) was evaluated in the study presented below by a team of American authors.

The interleukin 17 (IL-17) family represents a group of pro-inflammatory cytokines that play a crucial role in the pathogenesis of psoriasis. Inhibiting interleukins from this family has a significant anti-inflammatory effect and represents a promising therapeutic target for newly developed and applied drugs.

Cardiovascular (CV) diseases remain the leading cause of death among patients with type 2 diabetes (T2D). Reducing the incidence of macrovascular CV events in diabetics requires more than just glycemic control alongside all other present CV risk factors. New antidiabetic drugs represent a very promising group of medications with a favorable safety profile, aiding in reducing the risk of CV complications.